Revenue: As of FY2026 Q2, the actual value is USD 0.EPS: As of FY2026 Q2, the actual value is USD -1.38.EBIT: As of FY2026 Q2, the actual value is USD -7.617 M.<h3>Segment Revenue</h3><ul><li>The company did not generate any revenue for the three and six months ended September 30, 2025, and 2024, respectively.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: The net loss for the three months ended September 30, 2025, was $7.5 million, compared to $2.8 million for the same period in 2024. For the six months ended September 30, 2025, the net loss was $10.8 million, compared to $5.5 million in 2024.</li><li>Operating Expenses: Total operating expenses for the three months ended September 30, 2025, were $7.5 million, an increase of 166% from $2.8 million in 2024. For the six months ended September 30, 2025, operating expenses were $11.0 million, up 96% from $5.6 million in 2024.</li><li>Research and Development: R&amp;D expenses increased by 102% to $2.4 million for the three months ended September 30, 2025, and by 86% to $4.0 million for the six months ended September 30, 2025.</li><li>General and Administrative: G&amp;A expenses increased by 211% to $5.2 million for the three months ended September 30, 2025, and by 102% to $7.0 million for the six months ended September 30, 2025.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: Net cash used in operating activities was $6.4 million for the six months ended September 30, 2025, compared to $3.4 million in 2024.</li><li>Free Cash Flow: Not explicitly stated, but the net decrease in cash and cash equivalents was $1.7 million for the six months ended September 30, 2025.</li></ul><h3>Unique Metrics</h3><ul><li>Stock-Based Compensation: Significant increases in stock-based compensation expenses were noted, primarily due to stock option cancellation agreements, contributing to the rise in both R&amp;D and G&amp;A expenses.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company is focused on advancing its catheter-based technology for sensing and treating disorders of the nervous system, with ongoing clinical trials and product development efforts. The company completed a first-in-human proof-of-concept study and is expanding its clinical trials to include additional cancer-related pain indications.</li><li>Non-Core Business: The company has entered into agreements to potentially raise additional capital through the sale of common stock, which is crucial for funding ongoing operations and development efforts.</li><li>Priority: The company estimates it will require additional financing of approximately $30 to $36 million to fund operations to commercialization of its first indication.</li></ul>

Autonomix Medical | 10-Q: FY2026 Q2 Revenue: USD 0